Abstract Background The purpose of this study was to develop and validate the prostate cancer scale among the system of quality-of-life instruments for patients with cancer (QLICP-PR V2.0) to provide a reliable tool for assessing quality of life changes and clinical outcomes. Patients and Methods Application of programmed decision procedures, including multiple qualitative and quantitative analyses with general module and specific module combination pattern, were utilized to develop the QLICP-PR V2.0. On the basis of the data from 115 admitted and discharged patients with prostate cancer, the reliability, validity, and responsiveness of the QLICP-PR V2.0 scale were evaluated using correlation analysis, multi-trait scaling analysis, factor analysis, structural equation model, and paired t -tests, as well as combined with generalizability theory. Results Cronbach’s alpha, test–retest reliability, and intra-class correlation coefficient of the total scale were 0.886, 0.896, and 0.889, respectively. Correlation analysis and factor analysis confirmed good construct validity and criterion-related validity. The score differences at all five domains and the total scale before and after the treatment were statistically significant ( P < 0.05), with the SRM value ranging from − 1.152 to − 0.408, and the total scale was − 1.152. Generalizability theory results showed that the generalization coefficient of the five domains of the scale range from 0.575 to 0.764, and the reliability index between 0.529 and 0.748. Conclusions The QLICP-PR V2.0 has good psychometric properties in reliability, validity, and responsiveness, and can be used to evaluate the quality of life of patients with prostate cancer.
Wei et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: